Overactive bladder or non-neurogenic overactive bladder is a syndrome characterized by urinary urgency, frequency, nocturia and urgency incontinence.
It is not a disease but a symptom complex that generally is not a life-threatening condition. It is also known as bladder spasms.
Urgency is the complaint of sudden, compelling desire to pass urine that is difficult to deny. It is considered a hallmark symptom of overactive bladder.
Frequency is usually micturition of >7 episodes during waking hours.
Nocturia is the interruption of sleep one or more times because of the need to void.
Urgency incontinence is the involuntary leakage of urine associated with a sudden compelling desire to void.

  1. Apostolidis A. Antimuscarinics in the treatment of OAB: is there a first-line and a second-line choice?. Current Drug Therapies. 2015 May;15(4). doi: 10.2174/1389450116666150518102021. PMID: 25981605
  2. Arnold J, McLeod N, Thani-Gasalam, et al; Australian Family Physicians (incorporating Annals of General Practice); The Royal Australian College of General Practitioners. Overactive bladder syndrome - Management and treatment options. Aust Fam Physician. 2012 Nov;41(11):878-883. http://www.racgp.org.au/download/Documents/AFP/2012/November/201211arnold.pdf. PMID: 23145420
  3. Chapple C, Oelke M, Kapalan S, et al. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. Curr Med Res Opin. 2015 Jun;31(6):1201-1243. doi: 10.1185/03007995.2015.1032917. PMID: 25798911
  4. Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. PMID: 24127366
  5. Ellsworth P, Vincent M. Overactive bladder. eMedicine. http://emedicine.medscape.com/article/459340-overview. Apr 2014.
  6. European Association of Neurology. New drug therapies for LUTS discussed at the last Plenary Session. EAU. http://uroweb.org/new-drug-therapies-for-luts-discussed-at-the-last-plenary-session. Mar 2013.
  7. Filipetto F, Fulda K, HolthusenA, et al. The patient perspective on overactive bladder: a mixed methods needs assessment. BMC Family Practice. 2014 May;15:96. doi: 10.1186/147122961596.
  8. Foster H. Health insights: overactive bladder. HealthNation. http://www.healthination.com/digestive-urinary/insights-overactive-bladder.
  9. Gill P, Gewal N. Mirabegron: first β3 agonist in treatment of overactive bladder. Int J Basic Clin Pharmacol. 2012 Sep;1(2):120-121. doi: 10.5455/23192003.ijbcp002212.
  10. Gormley A, Lightner D, Burgio K, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. AUA. http://www.auanet.org/common/pdf/education/clinical-guidance/Overactive-Bladder.pdf. 2014.
  11. Hobbs C, Henderson J, Foley S. Results of intravesical botulinum toxin A in men with idiopathic overactive bladder symptoms. Journal of Clinical Urology. 2014 Aug;8(2):104-109. doi: 10.1177/2051415814546034.
  12. Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2013 Dec;6:1-16. doi: 10.2147/RRU.S40034. PMID: 24400248
  13. Maman K, Aballea S, Nazir J. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014 Apr;65(4):755-765. doi: 10.1016/j.eururo.2013.11.010. PMID: 24275310
  14. McKeage K. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. Clin Drug Investig. 2013 Jan;33(1):71-91. doi: 10.1007/s40261-012-0046-9. PMID: 23288694
  15. Mo Q, Wang Y, Ye Y, et al. Acupuncture for adults with overactive bladder: a systematic review protocol. BMJ Open. 2015 Jan;5(1):e006756. doi: 10.1136/bmjopen-2014-006756. PMID: 25573525
  16. Mudiwa L. The latest amendments to the overactive bladder clinical practice guidelines. Irish Medical Times. http://www.imt.ie/clinical/2014/09/the-latest-amendments-to-the-overactive-bladder-clinical-practice-guidelines.html. Jun 2013.
  17. National Clinical Guideline Centre. Clinical Guideline 148; Methods, evidence and recommendations; Commissioned by the National Institute for Health and Clinical Excellence. Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease. Final Version. NCGC. http://www.nice.org.uk/guidance/cg148/resources/cg148-urinary-incontinence-in-neurological-disease-full-guideline3. Aug 2012.
  18. The Cystitis & Overactive Bladder Foundation. Overactive bladder. COB. http://www.cobfoundation.org/overactive-bladder.
  19. U.S. Food and Drug Administration. FDA approves Botox to treat overactive bladder. US FDA. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336101.htm.
  20. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011 Mar;2011(2011):1-4. doi: 10.1155/2011/834753. PMID: 21687581
  21. Yeo EK, Hasim H, Abrams P. New therapies in the treatment of overactive bladder. Expert Opin Emerg Drugs. 2013 Sep;18(3):319-337. doi: 10.1517/14728214.2013.823156. PMID: 23885696
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.